CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 119 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q3 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $108,954,098 | -29.1% | 4,991,026 | +3.3% | 0.00% | -25.0% |
| Q2 2023 | $153,631,755 | +40.4% | 4,832,707 | +7.8% | 0.00% | +33.3% |
| Q1 2023 | $109,387,710 | -22.6% | 4,484,941 | +0.1% | 0.00% | -25.0% |
| Q4 2022 | $141,370,577 | +19.4% | 4,482,263 | +7.0% | 0.00% | 0.0% |
| Q3 2022 | $118,363,000 | +8.3% | 4,188,371 | +1.4% | 0.00% | 0.0% |
| Q2 2022 | $109,260,000 | -8.0% | 4,132,287 | +21.8% | 0.00% | +33.3% |
| Q1 2022 | $118,735,000 | +5.1% | 3,391,415 | -2.7% | 0.00% | 0.0% |
| Q4 2021 | $112,972,000 | +13.9% | 3,484,657 | +3.6% | 0.00% | 0.0% |
| Q3 2021 | $99,217,000 | +46.0% | 3,363,278 | +26.8% | 0.00% | +50.0% |
| Q2 2021 | $67,959,000 | +351.0% | 2,652,558 | +141.7% | 0.00% | – |
| Q1 2021 | $15,070,000 | -17.0% | 1,097,571 | +0.2% | 0.00% | -100.0% |
| Q4 2020 | $18,162,000 | – | 1,095,391 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,199,729 | $1,314,160,084 | 42.08% |
| Perceptive Advisors | 10,088,385 | $220,229,445 | 7.35% |
| Finepoint Capital LP | 563,345 | $12,297,821 | 6.12% |
| Affinity Asset Advisors, LLC | 685,061 | $14,954,882 | 4.21% |
| Paradigm Biocapital Advisors LP | 2,532,972 | $55,294,779 | 3.75% |
| Logos Global Management LP | 700,000 | $15,281,000 | 2.04% |
| Artal Group S.A. | 1,638,858 | $35,776 | 1.53% |
| Rock Springs Capital Management LP | 2,529,116 | $55,210,602 | 1.48% |
| GREAT POINT PARTNERS LLC | 215,000 | $4,693,450 | 0.86% |
| Frazier Life Sciences Management, L.P. | 393,000 | $8,579,190 | 0.57% |